India to have more than sufficient stock of Liposomal Amphotericin B drug for the treatment of Mucormycosis: Mansukh Mandaviya

New Delhi: “On 16^th June,2021, active cases of Mucormycosis were 27,142. Even in the future, if cases of Black fungus increases , India is prepared to have more than sufficient availability of Amphotericin B drug and other drugs which are required to treat patients of Mucormycosis. India has increased domestic production remarkably by more than fivefold. Domestic production of Liposomal Amphotericin B was just 62,000 vials in April,2021 and now it is expected to cross 3.75 lakh vials in June,2021. While increasing domestic production, India also placed order to import 9,05,000 Liposomal Amphotericin Bvials through M/s Mylan. India is leaving no stone unturned to boost the availability of  Amphotericin B drugs in the country’’, said Shri Mansukh Mandaviya, Minister of State for Chemicals & Fertilisers.

प्रधानमंत्री श्री @NarendraModi जी के नेतृत्व में ब्लैक फंगस के ईलाज में इस्तेमाल होने वाले इंजेक्शन लाइपोजोमल एंफोटेरिसिन-बी का देश के अंदर उत्पादन सिर्फ तीन महीने में बढ़ाकर पांच गुना से ज्यादा किया गया। pic.twitter.com/hspZmR8UmR

— Dr Mansukh Mandaviya (@mansukhmandviya) June 18, 2021

Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers has allocated a total 7,28,045 vials ofLiposomal Amphotericin B to all the states and Central institutions till 17^th June, 2021. Amphotericin B drug is used for the treatment of Mucormycosis, commonly known as Black Fungus.

State-wise allocation of Liposomal Amphotericin B Vials
from 11^th May, 2021 to 17^th June, 2021